Niterra Ventures Company invests $18M additional funding in neoplas med GmbH
Livingstone’s healthcare team in Düsseldorf has continued its advisory role for neoplas med GmbH in its third funding round. The Greifswald-based medical technology pioneer is intensifying its strategic collaboration with Niterra Ventures Company through an $18M capital increase to further expand the market for its innovative wound care technology products. With a total investment of $25M, Niterra Ventures Company previously invested in neoplas med in 2022 and 2023.
neoplas med, a spin-off from the Leibniz Institute for Plasma Science and Technology e.V. (INP), has created the argon cold plasma jet, kINPen® MED, an innovative ‘plasma pen’ that directs a precise plasma jet onto wounds and significantly accelerates wound healing. Clinical studies show that treatment time can be reduced by 50% compared to conventional methods – without side effects or developing resistance. neoplas med is almost the only company that uses the inert gas argon for this almost painless and rapid therapy, treating both infected and chronic wounds. With its ‘plasma pen’, neoplas med is the only manufacturer of cold plasma products in Europe that is certified under the European Medical Device Regulation (MDR).
“The additional investment by Niterra Ventures Company opens up completely new opportunities for us to tap into further markets, expand our technology platform and develop new products,” said Ulrike Sailer, CEO of neoplas med. “We are not only taking a big step forward, but also securing and creating new jobs in the high-tech sector.”
In Germany, 75% of university clinics and numerous medical practices and hospitals utilize neoplas med’s patented Argon Jet cold plasma therapy, which has been applied in more than 500,000 treatments worldwide, including in leading clinics in the Middle East. This funding will be used to further develop its technology platform and scale operations internationally, focusing primarily on the US, Europe and Middle East.
“Niterra Ventures Company is establishing new business opportunities in the medical, cleantech, energy and IoT sectors to improve quality of life using cutting-edge technologies,” said Dirk Schapeler, President of Niterra Ventures Company. “We have been working closely with neoplas med over the last few years and are excited to see the impact of the kINPen argon cold plasma on patients. Therefore, our follow-on investment was a logical step.”
As a part of its effort in the medical field, Niterra Ventures Company is investing in technology for detecting and assessing cardiology, oncology, neurology and hypertension conditions.
“We are proud to support neoplas med in its ambitious growth trajectory, facilitating the achievement of new milestones and continued success. Neoplas med’s cold plasma technology represents a substantial advancement in the healthcare sector, providing innovative solutions that enhance treatment efficacy and patient care across multiple medical disciplines,” said Dr. Ralf Nowak, Partner at Livingstone.
